$TENX

$1.72 +$0.08 (4.88%) Close

$TENX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 37.4M shares outstanding

Who owns TENX?

By type of holder

Institutions 80.3% Insiders 19.7% Everyone else 0.0%

Concentration Top 10 holders own 42.3%

FMR LLC 10.5% · Price T Rowe Associates Inc /MD/ 1.6%

Institutional ownership

80.3%

+22.6 pts vs last qtr

Institutional holders

110

+29 vs last qtr

Net shares bought

+8.5M

by institutions in Q2 2026

New / sold out

45 / 16

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

FMR LLC +3.6M
Vivo Capital, LLC +2.3M

Biggest sellers in Q2 2026

Price T Rowe Associates Inc /MD/ −2.3M
Janus Henderson Group PLC SOLD OUT −1.8M

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Tenax Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

+156.8%

+156.80% a year

Each share's claim on the business

−61.1%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $20.3M

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years69% Under 1 year31%

Quarterly turnover

65.0%

of institutional shares changed hands

Top 10 managers, median time held

1.5 years

Super Investors

Investment managers reporting TENX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
F FMR LLC	3.9M	10.53%	+3.6M (+1122.1%)	2025	0.0%
Shares held by quarter Peak holding3.9M (Q2'26) Change over 8 quarters+3.9M Share of the company10.530% FMR LLC's full portfolio →
PT Price T Rowe Associates Inc /MD/	607.7K	1.62%	−2.3M (−79.4%)	2025	0.0%
Shares held by quarter Peak holding3.0M (Q1'26) Change over 8 quarters+583.7K Share of the company1.620% Price T Rowe Associates Inc /MD/'s full portfolio →

FMR LLC

3.9M

% of company

10.53%

Change vs last qtr

+3.6M (+1122.1%)

Held since

2025

Price T Rowe Associates Inc /MD/

607.7K

% of company

1.62%

Change vs last qtr

−2.3M (−79.4%)

Held since

2025

28 more super investors behind a free account

See every manager holding Tenax Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting TENX on Form N-PORT; together they hold 15.4% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$12.4M	852.3K	2.28%	0.00%	June 30, 2026
IR iShares Russell 2000 ETF iShares Trust	$9.44M	648.8K	1.73%	0.01%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$12.4M

% of company

2.28%

% of the fund

0.00%

As of

June 30, 2026

iShares Russell 2000 ETF

iShares Trust

Position value

$9.44M

% of company

1.73%

% of the fund

0.01%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Tenax Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
CT Christopher Thomas Giordano 5%+ holder 13D · 4.3%	1.7M	4.52%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company4.520% Disclosed stake13D · 4.3% View the 13D/G filing →
DI Dellora Investments LP Insider	1.1M	2.81%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company2.810% Dellora Investments LP's insider activity →

Christopher Thomas Giordano

5%+ holder13D · 4.3%

1.7M

% of company

4.52%

Change vs last qtr

—

Held since

—

Dellora Investments LP

Insider

1.1M

% of company

2.81%

Change vs last qtr

—

Held since

—

7 more holders behind a free account

See every insider and 5%+ holder of Tenax Therapeutics Inc.

Comments